12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Apocept: Phase I started

Apogenix said it began an open-label, German Phase I trial to evaluate once-weekly 400 mg IV Apocept for 12 weeks in about 12 MDS patients. Apogenix also said FDA...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >